Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Saturday, July 5, 2008

2002 Bibliography prepared for the 2nd TMAU workshop : 1% may be affected ?

This 163 citations bibliography (January 1999 through August 2001) was prepared in support of the Second Workshop on Trimethylaminuria* held at the National Institutes of Health (NIH) on March 15-16, 2002, in Bethesda, Maryland

Full article :

PDF format :

Of particular interest is the introduction, where they elaborate on the general assumptions on TMAU from a genetic viewpoint at the time.

These include :

Many researchers believe that there are several types of TMAU caused by a "spectrum" of changes in the gene which controls the formation of the flavin-containing monooxygenase 3 (FMO3) enzyme. In humans, this is an important liver enzyme that controls the metabolism of substances such as TMA. The most severe form of TMAU appears to be caused by mutations in the FMO3 gene; these mutations appear inherited in an autosomal recessive fashion. Studies are leading many researchers to conclude that the less severe forms of TMAU are caused by several non-benign genetic polymorphisms in the FMO3 gene. Genetic polymorphisms are changes in the gene structure that may be fairly common in the population; however, for reasons, which are not well understood, these changes lead to TMAU-symptoms in certain individuals.

It is estimated that as much as one percent of the U.S. population may suffer from TMAU, but its true incidence is not yet known. But whether it is one or one-tenth of one percent, we know that the condition affects people of both sexes and of all ages and races from around the world. Currently there are more than 300 people with a malodor disorder on the Trimethylaminuria Support Group's mailing list, with many more preferring to remain anonymous because of the often-associated stigma, negative and harassing behaviors targeted at some, and the general lack of medical and other support.


Post a Comment